Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 283.62 Billion KRW | 95.84% |
| 2022 | 143.5 Billion KRW | 28.23% |
| 2021 | 112.61 Billion KRW | -24.92% |
| 2020 | 149.39 Billion KRW | 49.66% |
| 2019 | 97.92 Billion KRW | 7.19% |
| 2018 | 92.18 Billion KRW | -6.05% |
| 2017 | 100.01 Billion KRW | 13.8% |
| 2016 | 84.8 Billion KRW | 97.32% |
| 2015 | 42.16 Billion KRW | -40.18% |
| 2014 | 74.39 Billion KRW | 626.9% |
| 2013 | 10.23 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 45.37 Billion KRW | 24.81% |
| 2024 Q1 | 26.75 Billion KRW | -66.98% |
| 2023 Q3 | 149.82 Billion KRW | 3.79% |
| 2023 Q4 | 123.47 Billion KRW | -17.59% |
| 2023 FY | - KRW | 95.84% |
| 2023 Q1 | 42.35 Billion KRW | 49.2% |
| 2023 Q2 | 144.34 Billion KRW | 240.83% |
| 2022 Q3 | 47.88 Billion KRW | 36.37% |
| 2022 Q2 | 35.11 Billion KRW | 4.99% |
| 2022 Q1 | 33.44 Billion KRW | 165.97% |
| 2022 FY | - KRW | 28.23% |
| 2022 Q4 | 28.38 Billion KRW | -40.72% |
| 2021 Q1 | 28.29 Billion KRW | 36.96% |
| 2021 Q2 | 39.08 Billion KRW | 38.11% |
| 2021 Q3 | 32.99 Billion KRW | -15.59% |
| 2021 Q4 | 12.57 Billion KRW | -61.89% |
| 2021 FY | - KRW | -24.92% |
| 2020 Q1 | 32.02 Billion KRW | 11.08% |
| 2020 Q3 | 53.72 Billion KRW | 22.05% |
| 2020 Q4 | 20.66 Billion KRW | -61.55% |
| 2020 Q2 | 44.02 Billion KRW | 37.45% |
| 2020 FY | - KRW | 49.66% |
| 2019 Q2 | 24.31 Billion KRW | 11.3% |
| 2019 FY | - KRW | 7.19% |
| 2019 Q4 | 28.83 Billion KRW | 12.91% |
| 2019 Q3 | 25.53 Billion KRW | 5.03% |
| 2019 Q1 | 21.84 Billion KRW | -12.64% |
| 2018 Q3 | 25.82 Billion KRW | 7.26% |
| 2018 Q4 | 25 Billion KRW | -3.17% |
| 2018 FY | - KRW | -6.05% |
| 2018 Q2 | 24.07 Billion KRW | 27.57% |
| 2018 Q1 | 18.87 Billion KRW | -27.56% |
| 2017 Q1 | 22.57 Billion KRW | 0.0% |
| 2017 FY | - KRW | 13.8% |
| 2017 Q2 | 21.98 Billion KRW | -2.61% |
| 2017 Q3 | 29.2 Billion KRW | 32.81% |
| 2017 Q4 | 26.05 Billion KRW | -10.78% |
| 2016 Q1 | 14.41 Billion KRW | -13.46% |
| 2016 Q2 | 17.38 Billion KRW | 20.64% |
| 2016 Q3 | 28.66 Billion KRW | 64.83% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | - KRW | 97.32% |
| 2015 FY | - KRW | -40.18% |
| 2015 Q4 | 16.65 Billion KRW | -11.02% |
| 2015 Q3 | 18.71 Billion KRW | 388.88% |
| 2015 Q2 | -6.47 Billion KRW | -141.65% |
| 2015 Q1 | 15.55 Billion KRW | 27.03% |
| 2014 Q1 | 20.64 Billion KRW | 0.0% |
| 2014 FY | - KRW | 626.9% |
| 2014 Q2 | 23.01 Billion KRW | 11.52% |
| 2014 Q3 | 18.41 Billion KRW | -20.02% |
| 2014 Q4 | 12.24 Billion KRW | -33.47% |
| 2013 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -5737.922% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | -100.635% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 542.916% |
| HANDOK Inc. | 35.06 Billion KRW | -708.818% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 27461.832% |
| Yuhan Corporation | 127.43 Billion KRW | -122.569% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -655.911% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 1407.782% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 12.281% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -5583.519% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -1776.051% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -8190.792% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -6166.036% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -699.252% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -5737.922% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 1635.452% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -4226.889% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 675.401% |
| JW Holdings Corporation | 187.88 Billion KRW | -50.957% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 653.649% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -217.893% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 865.174% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -2047.12% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -2297.947% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -1420.388% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -5737.922% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -415.936% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | -71.985% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -217.893% |
| Yuhan Corporation | 127.43 Billion KRW | -122.569% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -747.254% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -3607.61% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -268.209% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -217.893% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -674.205% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -300.713% |
| CKD Bio Corp. | -1.63 Billion KRW | 17495.631% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -469.611% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -771.048% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -670.506% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 865.174% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -355.373% |
| Boryung Corporation | 114.28 Billion KRW | -148.167% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 1027.844% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -1776.051% |
| JW Lifescience Corporation | 50.82 Billion KRW | -457.998% |